Skip to main content
HHS Author Manuscripts logoLink to HHS Author Manuscripts
. Author manuscript; available in PMC: 2015 Oct 13.
Published in final edited form as: J Clin Virol. 2013 Jul 10;58(1):292–294. doi: 10.1016/j.jcv.2013.06.022

Comparison of PremierTM Rotaclone®, ProSpecTTM, and RIDASCREEN® Rotavirus Enzyme Immunoassay Kits for Detection of Rotavirus Antigen in Stool Specimens

Rashi Gautam 1, Freda Lyde 1, Mathew D Esona 1, Osbourne Quaye 1,2, Michael D Bowen 1,*
PMCID: PMC4602374  NIHMSID: NIHMS727316  PMID: 23850415

Abstract

Background

Rotaviruses are the major cause of severe dehydrating diarrhea in children throughout the world. Enzyme immunoassays (EIA) have been the standard method for detection of rotavirus in stool specimens since the 1980s. The World Health Organization (WHO) Rotavirus Surveillance Network has proposed including three EIA kits in the WHO-GSM (Global Management System/Système Mondial de Gestion ) catalogue for easy procurement of EIA kits by participating rotavirus surveillance network laboratories.

Objectives

In this study, we conducted a comparative analysis of 3 commercially available enzyme immunoassay kits: PremierTM Rotaclone® (Meridian Bioscience, Inc.), ProSpecTTM (Oxoid, Ltd.) and RIDASCREEN® (R-biopharm AG) for rotavirus diagnostics.

Study design

Using reverse-transcriptase-PCR (RT-PCR) as the gold standard, the 3 EIA kits were evaluated by testing a stool panel consisting of 56 rotavirus-positive and 54 rotavirus negative samples.

Results

The sensitivities of the PremierTM Rotaclone®, ProSpecTTM and RIDASCREEN® kits were 76.8%, 75% and 82.1% respectively, but did not differ significantly. The specificity of all the 3 kits was 100%. The use of RT-PCR as a gold standard lowered the observed sensitivity of all 3 EIA kits but helps to reduce equivocal results that can be seen when another EIA or other non-molecular methods are used as the reference assay in comparison studies.

Conclusion

Our study found that all three kits are suitable for use by rotavirus surveillance programs.

Keywords: rotavirus, EIA, comparison, RT-PCR, sensitivity, specificity

Background

Group A rotaviruses are the leading cause of acute gastroenteritis (AGE) in infants and young children worldwide1, 2. Enzyme immunoassays (EIAs) offer a simple, rapid, and sensitive method for routine laboratory detection of rotavirus antigen in stool specimens3. Commercial EIA kits have been available since the 1980s and evaluations of these kits have been performed3-5, but a comparison of current generation EIA kits has not been done. The Rotavirus Surveillance Laboratory, Centers for Disease Control and Prevention, Atlanta, Georgia, USA is the Global Reference Laboratory for the World Health Organization (WHO) Rotavirus Surveillance Network.

Objectives

To assist the WHO in recommending the best commercially available kits for rotavirus detection to laboratories that participate in the global network, we conducted a comparative analysis study of 3 EIA kits in order to determine if these 3 kits meet performance criteria required for inclusion in the WHO-GSM (Global Management System/Système Mondial de Gestion) catalogue to facilitate reagent procurement by network surveillance laboratories. The EIA kits included in this study were: 1) the PremierTM Rotaclone® (Meridian Bioscience, Inc., Cincinnati OH, USA); 2) the ProSpecTTM Rotavirus Microplate Assay (Oxoid, Ltd., Basingstoke, Hampshire, UK); and the 3) RIDASCREEN® Rotavirus (R-Biopharm AG, Darmstadt, Germany). All 3 kits use a solid-phase sandwich EIA format. The PremierTM Rotaclone® kit is the only multi-well EIA kit approved by the U.S. Food and Drug Administration (FDA) for in vitro diagnostic (IVD) use. It uses monoclonal antibodies raised against rotavirus structural protein VP6. The ProSpecTTM Rotavirus Microplate Assay EIA kit is a replacement kit for the widely-used rotavirus IDEIATM Rotavirus EIA (Dako Diagnostics Ltd., Ely UK), which was discontinued in March 2009. It uses polyclonal capture and detector antibodies raised against rotavirus structural proteins. The RIDASCREEN® Rotavirus EIA kit uses monoclonal antibodies raised against rotavirus structural protein VP6. In 2010, RIDASCREEN® was reformulated to incorporate a biotinylated detector antibody and streptavidin-conjugated peroxidase. The analytical performance of these kits has not been compared directly.

Study Design

Stool samples from AGE cases were selected from domestic and international surveillance samples received by the CDC for genotyping of rotavirus strains. All the samples selected for this study were tested for the presence of rotavirus VP4 and VP7 and/or VP6 genes using reverse transcription-PCR (RT-PCR)6-8. Fifty-six rotavirus-positive samples and 54 rotavirus-negative samples were selected for this study. All 110 samples were tested for rotavirus antigen according to manufacturers’ instructions for each kit. Three operators performed all tests, for a total of 3 replicates per sample. EIA plates were read on an MRXe ELISA plate reader (Dynex Technologies, Chantilly, VA USA). A sample was considered to test positive by a kit if the optical density (OD) values for 2 or 3 replicates were above the calculated cut-off value for that kit. The analytical sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) were calculated for each kit. Statistical analyses were performed by using Prism Version 5.02 Software for Windows (GraphPad Software, Inc., La Jolla, CA). Testing results were analyzed by chi-square test. OD values were compared by Kruskal-Wallis test, and pairwise comparisons mean OD values from each kit were performed using Dunn’s Multiple Comparison test.

Results

The results of testing 110 samples in triplicate by each kit are shown (Table 1). For each of the 3 kits, all EIA-positive samples had tested as rotavirus-positive by RT-PCR for VP4 and VP7 or VP6 and all EIA-negative samples had tested negative by RT-PCR. However, some RT-PCR positive samples tested negative by EIA, ranging from 10 for RIDASCREEN® Rotavirus to 14 for ProSpecTTM. Using RT-PCR as the gold standard, the performance characteristics of the kits were: PremierTM Rotaclone® EIA, 76.8% sensitivity, 100% specificity, PPV = 100% , NPV = 80.6%; ProSpecTTM EIA, 75% sensitivity, 100% specificity, PPV = 100%, NPV = 79.4%; and, RIDASCREEN® Rotavirus, 82.1% sensitivity, 100% specificity, PPV = 100%, NPV = 84.4%. When the sample testing results of the 3 kits, expressed as positives and negatives, were analyzed by chi-square test (Table 1), the results obtained by each kit were not found to differ significantly. Distribution plots of OD values for the 3 kits (n = 330; Figure 1) showed that the distribution for the PremierTM Rotaclone® and ProSpecTTM Rotavirus kits were similar, with each plot skewed to the right. For both assays, numerous data points lay within 0.05 OD units on either side of the cut-off value (Rotaclone®, n=23; ProSpecT™, n=20). In contrast, for the RIDASCREEN® kit, OD values were bimodally distributed, with one large peak on the left side of the graph containing all the negative values, and a broad peak on the right side containing the majority of the positive OD values. Only 1 data point lay within 0.05 OD units on either side of the cut-off value. The OD values from the 3 kits were found to differ significantly, and this difference was observed when all data points were analyzed (p = 0.0131), when positive OD values only were analyzed (p < 0.001), and when negative OD values only were analyzed (p < 0.001). Pairwise comparisons showed that the OD values from the RIDASCREEN® kit differed significantly (p < 0.05) from those of the ProSpecT™ kit but did not differ significantly from those of the Rotaclone® kit. The OD values generated by the PremierTM Rotaclone® and ProSpecTTM kits did not differ significantly. We found the PremierTM Rotaclone® EIA to have 76.8% sensitivity and 100% specificity compared with 100% sensitivity and 92% specificity as reported by its manufacturer, Meridian Bioscience, Inc. and 100% sensitivity and 99-100% specificity as reported in published studies.3, 5. The ProSpecTTM Rotavirus EIA kit exhibited 75% sensitivity and 100% specificity in this study as compared with 100% sensitivity and 99.2% specificity as reported by Oxoid, Ltd. RIDASCREEN® EIA showed 82.1% sensitivity and 100% specificity as compared to 98.4% sensitivity and 100% specificity as reported by R-biopharm AG. The differences between the sensitivity and specificity values that we found and those reported by the manufacturers and others results from using different gold standard methods. We used RT-PCR as a gold standard whereas Meridian Bioscience compared PremierTM Rotaclone® EIA results to electron microscopy (EM) and other studies used a reference EIAs3, 5. Oxoid compared ProSpecTTM Rotavirus EIA results to EM and a commercial EIA kit, and R-Biopharm compared RIDASCREEN® EIA results to other certified EIA kit results. The use of the more sensitive RT-PCR technique9 for establishing the gold-standard lowers the observed sensitivity of all 3 EIA kits but helps to reduce equivocal results that can be seen when another EIA or other methods are used as the reference assay in comparison studies 3, 5 _ENREF_3. In May 2010, Oxoid Ltd. changed the method used to calculate the cut-off value of ProSpecTTM Rotavirus kit by specifying that cut-off limit should be calculated by adding 0.2 absorbance units to the negative control value; previously 0.1 absorbance units were added. When the ProSpecTTM Rotavirus results from this study were reinterpreted using a cut-off value calculated using the original method, the sensitivity increased to from 75 to 87.5%, surpassing sensitivity attained by the RIDASCREEN® kit. Oxoid Ltd. changed the method of calculating the cut-off limit for the ProSpecTTM kit so that its performance would be equivalent to that of the IDEIATM kit, which it replaced. However, this change appears to have reduced the sensitivity of the ProSpecTTM Rotavirus kit.

Table 1.

Comparison of Rotavirus Detection Results by Premiere Rotaclone®, ProSpecT ™ Rotavirus and RIDASCREEN® Rotavirus EIA kits using RT-PCR as the Gold Standard.

EIA Kit RT-PCR Total
Positive Negative
Rotaclone
Positive 43 0 43 a
Negative 13 54 67 a
Total 56 54 110
ProSpecT
Positive 42 0 42 a
Negative 14 54 68 a
Total 56 54 110
RIDASCREEN
Positive 46 0 46 a
Negative 10 54 64 a
Total 56 54 110
a

Results obtained by each kit were not found to differ significantly (p = 0.8483, Chi-square = 0.3291, df = 2)

Figure 1.

Figure 1

Frequency distributions of OD values for the PremierTM Rotaclone®, ProSpecTTM Rotavirus, and RIDACREEN® Rotavirus EIA kits. Bins (logical ranges) were set at every 0.05 OD units. The vertical dashed line on each graph indicates the assay cut-off value. The y-axis of the bottom graph has been condensed between 100 and 180 to maintain the visibility of the shorter data bars.

Conclusions

In this study, we evaluated and compared 3 EIA kits, PremierTM Rotaclone®, ProSpecTTM Rotavirus, and RIDASCREEN® Rotavirus for detection of rotavirus antigen in stool samples. Testing of the kits against a stringent gold standard showed them to have comparable sensitivity and specificity, thus, all 3 kits are suitable for use in rotavirus surveillance programs worldwide.

Acknowledgment

We wish to thank Fatima Serhan and Mary Agocs, WHO-Geneva, for their support of this study. We wish to thank Mary McCauley for editorial assistance.

Abbreviations

AGE

acute gastroenteritis

EIA

Enzyme immunoassay

ELISA

Enzyme-linked Immunosorbent Assay

FDA

Food and Drug Administration

GSM

Global Management System/Système Mondial de Gestion

IVD

in vitro diagnostic

NPV

negative predictive value

OD

optical density

PPV

positive predictive value

WHO

World Health Organization

Footnotes

Institution where work was performed: National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, 1600 Clifton Rd. NE, Atlanta, GA, 30333, USA

Disclaimer: The findings and conclusions in this report are those of the author(s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention. Names of specific vendors, manufacturers, or products are included for public health and informational purposes; inclusion does not imply endorsement of the vendors, manufacturers, or products by the Centers for Disease Control and Prevention, the US Department of Health and Human Services, or the World Health Organization.

Conflict of Interest Declarations

The following additional information is required for submission. Please note that failure to respond to these questions/statements will mean your submission will be returned to you. If you have nothing to declare in any of these categories then this should be stated.

Please state any conflict of interests. A conflict of interest exists when an author or the author's institution has financial or personal relationships with other people or organisations that inappropriately influence (bias) his or her actions. Financial relationships are easily identifiable, but conflicts can also occur because of personal relationships, academic competition, or intellectual passion. A conflict can be actual or potential, and full disclosure to The Editor is the safest course.

Please state any sources of funding for your research

WHO, CDC

Please state whether Ethical Approval was given, by whom and the relevant Judgement’s reference number

Not applicable.

If you are submitting a Randomized Controlled Trial, please state the International Standard Randomised Controlled Trial Number (ISRCTN)

Not applicable.

References

  • 1.Parashar UD, Gibson CJ, Bresse JS, Glass RI. Rotavirus and severe childhood diarrhea. Emerg Infect Dis. 2006;12:304–6. doi: 10.3201/eid1202.050006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Tate JE, Burton AH, Boschi-Pinto C, Steele AD, Duque J, Parashar UD, et al. 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12:136–41. doi: 10.1016/S1473-3099(11)70253-5. [DOI] [PubMed] [Google Scholar]
  • 3.Dennehy PH, Gauntlett DR, Tente WE. Comparison of nine commercial immunoassays for the detection of rotavirus in fecal specimens. J Clin Microbiol. 1988;26:1630–4. doi: 10.1128/jcm.26.9.1630-1634.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Christy C, Vosefski D, Madore HP. Comparison of three enzyme immunoassays to tissue culture for the diagnosis of rotavirus gastroenteritis in infants and young children. J Clin Microbiol. 1990;28:1428–30. doi: 10.1128/jcm.28.6.1428-1430.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Lipson SM, Svenssen L, Goodwin L, Porti D, Danzi S, Pergolizzi R. Evaluation of two current generation enzyme immunoassays and an improved isolation-based assay for the rapid detection and isolation of rotavirus from stool. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology. 2001;21:17–27. doi: 10.1016/s1386-6532(00)00181-5. [DOI] [PubMed] [Google Scholar]
  • 6.Iturriza Gomara M, Wong C, Blome S, Desselberger U, Gray J. Molecular characterization of VP6 genes of human rotavirus isolates: correlation of genogroups with subgroups and evidence of independent segregation. J Virol. 2002;76:6596–601. doi: 10.1128/JVI.76.13.6596-6601.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Gentsch JR, Glass RI, Woods P, Gouvea V, Gorziglia M, Flores J, et al. Identification of group A rotavirus gene 4 types by polymerase chain reaction. J Clin Microbiol. 1992;30:1365–73. doi: 10.1128/jcm.30.6.1365-1373.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Das BK, Gentsch JR, Cicirello HG, Woods PA, Gupta A, Ramachandran M, et al. Characterization of rotavirus strains from newborns in New Delhi, India. J Clin Microbiol. 1994;32:1820–2. doi: 10.1128/jcm.32.7.1820-1822.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Wilde J, Yolken R, Willoughby R, Eiden J. Improved detection of rotavirus shedding by polymerase chain reaction. Lancet. 1991;337:323–6. doi: 10.1016/0140-6736(91)90945-l. [DOI] [PubMed] [Google Scholar]

RESOURCES